Virax Biolabs (VRAX) Receivables (2021)
Virax Biolabs (VRAX) posted quarterly Receivables of $928.0 for Q1 2021.
Virax Biolabs (VRAX) Receivables (2021) Analysis & Trends
Virax Biolabs' Receivables history runs 1 years deep, the most recent figure standing at $928.0 for Q1 2021.
- In Q1 2021, Receivables changed N/A year-over-year to $928.0; the TTM figure through Mar 2021 stood at $928.0 (changed N/A YoY), while the FY2021 annual figure was $928.0, changed N/A from the prior year.
- Receivables for Q1 2021 stood at $928.0.
- The five-year high for Receivables was $928.0 in Q1 2021, with the low at $928.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 928.00 |